LiPlasome Pharma Ltd. has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). This provides a targeted treatment limiting the destruction of healthy cells as well as side effects.

This will significantly improve the treatment with chemotherapy within a number of cancer diseases as LiPlasome’s technology significantly improves the balance between effect and side effect. Investment carried out in 2005.

www.liplasome.com